Corporate Sites

Virtual Broadcast: 5 Years Strong, The Impact of Long-Term ECHELON-1 Data in Stage III/IV CHL   Jan 21, 2021 at 6:30 pm and 9 pm EST

Contact in CT:

Jessi Scorrano

Senior Oncology Account Manager - Connecticut

Breast Cancer

jscorrano@seagen.com

914-260-2000

Toni Ann Rotondo,

Senior Oncology Account Manager, Hartford Territory

trotondo@seagen.com

203-218-0485

Ginger Ginelli

gifi@genmab.com

Kelly Robin

krobin@seagen.com

Important News and Information

U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer  07/09/2021

Seattle Genetics Announces U.S> FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

04/17/2020

Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer  02/19/2020